CLOSED
REQUEST FOR APPLICATIONS
Letters of intent must be submitted through the online portal by 5pm ET on March 1, 2023.
The Samuel Waxman Cancer Research Foundation (SWCRF) and The Mark Foundation for Cancer Research are pleased to issue a joint Request for Applications (RFA) for collaborative projects to focus on Aging and Cancer. Projects must include collaborations between two laboratories with different but complementary expertise. Proposals must justify the partnership through synergistic scientific aims. Awards will provide $500,000 total over three years ($250,000 to each PI).
Examples of potential research topics to understand and prevent the rising incidence of cancer due to aging include, but are not limited to:
- Senolytics, anti-inflammatory agents, and specific targets to enhance healthy longevity and diminish cancer incidence
- Impact of the aged microenvironment on the immune system, tumor progression, therapy response, and recurrent disease
- Biomarkers to evaluate aging and cancer risk such as clonal hematopoiesis, epigenetics patterns, DNA repair, mutations, and telomeres
- Approaches to limit therapy-associated cancer in older individuals and to establish how aging affects the response to treatment for cancer
Long-Term Goals - Recipients of these research awards are encouraged to develop collaborations that extend beyond the term of the grant and form a society of investigators committed to:
Collaboration:
- Formulation of research plans to augment other SWCRF /Mark Foundation programs
- Sharing of research materials, reagents, and/or core resources
- Joint publications
- Development of program project grants (P01s) and/or collaborative R01s
Communication:
- Interactions at the annual SWCRF Scientific Review Meeting and the annual Mark Foundation Scientific Symposium
- Subgroup meetings at other meetings such as AACR
2023 RFA Guidelines
Teams consisting of two principal Investigators from two different institutions may apply for a three-year grant for up to $500,000 (for each PI: $100,000 distributed in Years 1 and 2 and $50,000 in Year 3), which may include indirect costs up to 10% direct costs).
The RFA will use a two stage process. In the first phase a one page, structured letter of intent will be reviewed by a panel from the SWCRF and Mark Foundation. A select number of applications will be invited to submit a full application.
Timeline:
Submit one-page letter of intent (Arial 11 pt. 0.5-inch margin, using the outline below ) March 1, 2023
Invitations for Full Application April 15, 2023
Full application June 1, 2023
Funding decision July15, 2023
Funding begins October 1, 2023
Invitations for full applications and funding decisions will be based on peer review by a committee of members of the SWCRF Scientific Advisory Board and Mark Foundations representatives.
Letters of intent must be submitted through the online portal by 5pm ET on March 1, 2023.
Letter of Intent format: 1 page, 0.5 inch border, arial 11 type:
- Proposal Title
- Background
- Key preliminary data
- Premise and rigor of underlying research
- Hypothesis
- Specific Aims
- Novelty
- Potential Translational Impact for cancer and aging and cancer
Submit all inquiries to [email protected].
About the Samuel Waxman Cancer Research Foundation
The Samuel Waxman Cancer Research Foundation (SWCRF), founded in 1975, is a non-profit organization dedicated to conducting basic, translational, and clinical research with the goal of developing effective targeted treatments for cancer. SWCRF funds research in leading institutions in the United States, Canada, China, and Israel; fosters collaborations; trains scientists; and organizes international conferences to develop novel approaches to prevent and treat cancer. SWCRF develops research programs in the form of an “Institution Without WallsÔ” that spans institutions and disciplines and seeks to identify investigators who are best able to attack specific problems related to cancer. To date, the SWCRF has awarded more than $100 million to more than 200 investigators.
About the Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research actively partners with scientists, research institutions and philanthropic organizations around the world to accelerate research that will transform the prevention, diagnosis and treatment of cancer. Since 2017, The Mark Foundation has awarded more than $190 million in grants to enable innovative basic, translational and clinical cancer research, including drug discovery. In 2022, The Mark Foundation received an additional $500 million commitment to fund cutting-edge cancer research in its first decade. The Mark Foundation also has a robust and growing portfolio of investments in oncology companies developing novel therapeutics and diagnostics. Through its research and venture arms, The Mark Foundation supports projects throughout their life cycle to ensure their highest chance of success in impacting the lives of patients with breakthroughs in cancer care.